Act A — The Pathway Specificity Problem
An FDA 510k clearance submission for a wearable cardiac monitoring device is not the same document as a 510k for an in vitro diagnostic. Both are 510k submissions. Both require the same general structure. But the predicate device identification strategy, the substantial equivalence argumentation, the performance testing protocol citations, and the special controls framework are specific to the device category — and a technical writer who has filed fifteen 510ks for IVDs has processed none of the device-specific clinical evidence standards that FDA's Division of Cardiovascular Devices applies.
The company hiring a regulatory technical writer cannot see this distinction from a resume that says "510k submissions, FDA experience, Class II devices." The writer themselves may not recognize it as a meaningful distinction. The FDA will recognize it eleven months later, in a Deficiency Letter.
Act B — The Story
Nadia had three months to retain a technical writer and eleven months before she expected clearance. Her company had raised a $4M Series A with a commercialization milestone tied to FDA 510k submission.
Her search started with her regulatory affairs network — two contacts from a prior employer, a referral from her device contract manufacturer, a post in a MedTech Slack channel. She received five names. She screened them by 510k volume and chose the writer with the longest submission record: fourteen IVD submissions over eight years.
The submission was filed on schedule. The review began. At month eleven, the FDA issued a Deficiency Letter: the substantial equivalence argumentation cited predicate devices in a device category that FDA's cardiovascular division did not recognize as substantially equivalent to the proposed device, and the performance testing citations did not include the agency's specific guidance for wearable cardiac monitoring devices — which had been updated in a 2023 guidance document the writer had not been monitoring.
Nadia's company faced a six-month reconstruction timeline. The Series A milestone was missed.
She found the platform while searching for a replacement writer. She registered the need: FDA 510k, cardiovascular monitoring device, wearable, device-specific performance testing experience, 2023 cardiac device guidance familiarity, reconstruction of prior submission.
James appeared in the first match result. His profile documented twelve 510k submissions in the cardiovascular and neural device categories, including two that had addressed the 2023 wearable cardiac monitoring guidance update. He had flagged that guidance on his platform profile as a current active document — the platform's regulatory intelligence feed had pushed it to him nine months earlier.
The reconstruction took six weeks. The resubmission received clearance in four months.
Act C — Why This Market Stays Broken Without Infrastructure
James was discoverable — on LinkedIn, with a complete submission record, with cardiovascular device submissions listed. The signal that distinguished him from the writer Nadia had originally hired was his device-category-specific 510k history and his 2023 guidance currency. Those signals were not in any directory she had access to.
"510k experience, Class II devices" is the category. "510k cardiovascular monitoring, post-2023 guidance" is the subspecialty. The distinction is invisible until the Deficiency Letter arrives.
Thin market infrastructure makes that distinction searchable before the submission clock starts — encoding the device category and guidance version experience that defines the match, at the moment when a wrong match costs eleven months.
Characters are fictional. FDA 510k submission requirements, cardiovascular device division review standards, and the 2023 wearable cardiac monitoring device guidance framework are real. DeeperPoint is building the infrastructure this story describes.